2022
DOI: 10.1111/jdi.13945
|View full text |Cite
|
Sign up to set email alerts
|

Updates of incretin‐related drugs for the treatment of type 2 diabetes

Abstract: Mechanisms of dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists and glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor dual‐agonist in glycemic control and/or weight loss.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 23 publications
0
0
0
Order By: Relevance